New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 22, 2013
14:33 EDTISISIsis Pharmaceuticals provides update on CHMP Opinion on KYNAMRO
Isis Pharmaceuticals announced that following Genzyme's request for re-examination, the Committee for Medicinal Products for Human Use of the European Medicines Agency confirmed its previous position and has maintained a negative opinion regarding the marketing authorization application for KYNAMROTM (mipomersen) as a treatment for patients with Homozygous Familial Hypercholesterolaemia. The FDA approved KYNAMRO in the United States in January for the treatment of patients with Homozygous Familial Hypercholesterolaemia.
News For ISIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 16, 2014
07:06 EDTISISIsis Pharmaceuticals initiates phase 1/2 study of ISIS-DMPK Rx
Subscribe for More Information
December 11, 2014
09:28 EDTISISIsis Pharmaceuticals up 3% after CEO appears on Mad Money
Subscribe for More Information
December 8, 2014
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use